Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance? |
| |
Authors: | H J McKenna |
| |
Institution: | (1) Department of Immunobiology, Immunex Corporation, 51 University street, Seattle, WA 98101-2936, USA e-mail: mckenna@immunex.com Fax: +1-206-301-1061, US |
| |
Abstract: | flt3 ligand (FL) is a growth factor that induces hematopoietic progenitor cell and dendritic cell (DC) expansion when administered
to mice. Lymphoid-related (CD8α+) and myeloid-related (CD8α−) DC are transiently expanded in multiple tissues. Treatment of tumor-bearing mice with FL results in slower tumor growth
and, in some cases, tumor rejection and the development of tumor-specific T cell immunity. The clinical use of DC as cellular
vehicles for tumor antigen presentation to generate a tumor-specific T cell response is under investigation. DC are currently
generated ex vivo, pulsed with antigen, and then infused into patients, and much effort is being directed toward optimizing
each of these steps. Administration of FL to humans induces a profound increase in circulating DC. The availability of a large
number of DC generated in vivo has important implications for tumor immunotherapy approaches.
Received: 13 May 1999 / Accepted: 14 June 1999 |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|